Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameAnti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)
Drug Alias NameKN5601KN-5601
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsNatural killer cell replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicMucocutaneous Lymph Node Syndrome +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe Children'S Hospital, Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesThe Children'S Hospital, Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicMucocutaneous Lymph Node Syndrome +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A